(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin...
Stats | |
---|---|
आज की मात्रा | 4 951.00 |
औसत मात्रा | 30 523.00 |
बाजार मूल्य | 0.00 |
EPS | $0 ( 2022-04-11 ) |
Last Dividend | $0.104 ( 2021-02-24 ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.35 |
ATR14 | $0.324 (12.13%) |
मात्रा सहसंबंध
Biofrontera AG सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
SOHU | 0.914 |
CHB | 0.904 |
NWL | 0.904 |
CSSEP | 0.903 |
TSRI | 0.902 |
AOUT | 0.902 |
HPK | 0.9 |
BMRA | 0.897 |
MODV | 0.897 |
OGI | 0.895 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
APXI | -0.914 |
WINV | -0.908 |
FRSG | -0.907 |
KAII | -0.906 |
ZEUS | -0.906 |
MLAI | -0.905 |
MATW | -0.904 |
ALSA | -0.904 |
MSAC | -0.903 |
PTOC | -0.903 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Biofrontera AG सहसंबंध - मुद्रा/वस्त्र
Biofrontera AG वित्तीय
Annual | 2020 |
राजस्व: | $30.35M |
सकल लाभ: | $26.81M (88.35 %) |
EPS: | $-0.467 |
FY | 2020 |
राजस्व: | $30.35M |
सकल लाभ: | $26.81M (88.35 %) |
EPS: | $-0.467 |
FY | 2019 |
राजस्व: | $31.27M |
सकल लाभ: | $26.39M (84.41 %) |
EPS: | $-0.312 |
FY | 2018 |
राजस्व: | $21.11M |
सकल लाभ: | $16.66M (78.91 %) |
EPS: | $-0.389 |
Financial Reports:
No articles found.
Biofrontera AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0221 | 2020-03-18 |
Last Dividend | $0.104 | 2021-02-24 |
Next Dividend | $0 | N/A |
Payout Date | 2021-03-04 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.126 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 0.6 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2020 | $0.0221 | 0.22% |
2021 | $0.104 | 1.30% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.429 | 1.500 | -8.58 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.231 | 1.200 | -7.70 | -9.24 | [0 - 0.3] |
returnOnEquityTTM | -1.503 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.48 | 0.800 | 0.0937 | 0.0750 | [0.8 - 2.5] |
cashRatioTTM | 1.997 | 1.500 | 0.0174 | 0.0262 | [0.2 - 2] |
debtRatioTTM | 0.423 | -1.500 | 2.94 | -4.42 | [0 - 0.6] |
interestCoverageTTM | -2.47 | 1.000 | -2.03 | -2.03 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.102 | 2.00 | -0.0341 | -0.0683 | [0 - 30] |
freeCashFlowPerShareTTM | -0.130 | 2.00 | -0.0651 | -0.130 | [0 - 20] |
debtEquityRatioTTM | 3.24 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.883 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.251 | 1.000 | -7.02 | -7.02 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.119 | 1.000 | -1.774 | -1.774 | [0.2 - 2] |
assetTurnoverTTM | 0.538 | 0.800 | 9.75 | 7.80 | [0.5 - 2] |
Total Score | -0.244 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.33 | 1.000 | -0.640 | 0 | [1 - 100] |
returnOnEquityTTM | -1.503 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.130 | 2.00 | -0.0434 | -0.130 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.102 | 2.00 | -0.0341 | -0.0683 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -2.28 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0939 | 1.000 | -4.85 | 0 | [0.1 - 0.5] |
Total Score | -2.56 |
Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं